217 related articles for article (PubMed ID: 31833567)
1. Myeloproliferative and lymphoproliferative disorders: State of the art.
Rumi E; Baratè C; Benevolo G; Maffioli M; Ricco A; Sant'Antonio E
Hematol Oncol; 2020 Apr; 38(2):121-128. PubMed ID: 31833567
[TBL] [Abstract][Full Text] [Related]
2. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
Edahiro Y
Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
Quintás-Cardama A; Verstovsek S
Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative disorders.
Levine RL; Gilliland DG
Blood; 2008 Sep; 112(6):2190-8. PubMed ID: 18779404
[TBL] [Abstract][Full Text] [Related]
5. SOHO State-of-the-Art Update and Next Questions: MPN.
Bose P; Gotlib J; Harrison CN; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):1-12. PubMed ID: 29277359
[TBL] [Abstract][Full Text] [Related]
6. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.
Mascarenhas J; Mughal TI; Verstovsek S
Curr Med Chem; 2012; 19(26):4399-413. PubMed ID: 22830345
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of JAK2 inhibitors.
Verstovsek S
Hematology Am Soc Hematol Educ Program; 2009; ():636-42. PubMed ID: 20008249
[TBL] [Abstract][Full Text] [Related]
8. The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
Mazzacurati L; Collins RJ; Pandey G; Lambert-Showers QT; Amin NE; Zhang L; Stubbs MC; Epling-Burnette PK; Koblish HK; Reuther GW
Blood Adv; 2019 Nov; 3(22):3503-3514. PubMed ID: 31725895
[TBL] [Abstract][Full Text] [Related]
9. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Walz C; Cross NC; Van Etten RA; Reiter A
Leukemia; 2008 Jul; 22(7):1320-34. PubMed ID: 18528425
[TBL] [Abstract][Full Text] [Related]
10. Does Double Mean Trouble? Coexistence of Myeloproliferative and Lymphoproliferative Neoplasms.
Lekovic D; Ivanovic J; Terzic T; Perunicic Jovanovic M; Dencic Fekete M; Jovanovic J; Arsenovic I; Vukovic V; Bila J; Bogdanovic A; Antic D
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542040
[No Abstract] [Full Text] [Related]
11. The Myeloproliferative Neoplasm Landscape: A Patient's Eye View.
Petruk C; Mathias J
Adv Ther; 2020 May; 37(5):2050-2070. PubMed ID: 32329011
[TBL] [Abstract][Full Text] [Related]
12. Deactylase inhibition in myeloproliferative neoplasms.
Mithraprabhu S; Grigoriadis G; Khong T; Spencer A
Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S50-7. PubMed ID: 21127942
[TBL] [Abstract][Full Text] [Related]
13. Achievements and future outlook for JAK inhibitors in polycythaemia vera.
Cakmak I; Harrison C
Expert Opin Pharmacother; 2023; 24(13):1491-1496. PubMed ID: 37343285
[TBL] [Abstract][Full Text] [Related]
14. Myeloproliferative neoplasms: from origins to outcomes.
Nangalia J; Green AR
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):470-479. PubMed ID: 29222295
[TBL] [Abstract][Full Text] [Related]
15. Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
Nair PC; Piehler J; Tvorogov D; Ross DM; Lopez AF; Gotlib J; Thomas D
Blood Cancer Discov; 2023 Sep; 4(5):352-364. PubMed ID: 37498362
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.
Hasselbalch HC; Skov V; Kjær L; Ellervik C; Poulsen A; Poulsen TD; Nielsen CH
Cytokine Growth Factor Rev; 2021 Aug; 60():28-45. PubMed ID: 33992887
[TBL] [Abstract][Full Text] [Related]
17. Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib.
Adesola AA; Cozma MA; Chen YF; Srichawla BS; Găman MA
World J Hepatol; 2023 Nov; 15(11):1188-1195. PubMed ID: 38075009
[TBL] [Abstract][Full Text] [Related]
18. Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable.
Codilupi T; Szybinski J; Arunasalam S; Jungius S; Dunbar AC; Stivala S; Brkic S; Albrecht C; Vokalova L; Yang JL; Buczak K; Ghosh N; Passweg JR; Rovo A; Angelillo-Scherrer A; Pankov D; Dirnhofer S; Levine RL; Koche R; Meyer SC
Clin Cancer Res; 2024 Feb; 30(3):586-599. PubMed ID: 37992313
[TBL] [Abstract][Full Text] [Related]
19. Current therapies for classic myeloproliferative neoplasms: A focus on pathophysiology and supportive care.
Chung C
Am J Health Syst Pharm; 2023 Nov; 80(22):1624-1636. PubMed ID: 37556726
[TBL] [Abstract][Full Text] [Related]
20. New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.
Arwood ML; Liu Y; Harkins SK; Weinstock DM; Yang L; Stevenson KE; Plana OD; Dong J; Cirka H; Jones KL; Virtanen AT; Gupta DG; Ceas A; Lawney B; Yoda A; Leahy C; Hao M; He Z; Choi HG; Wang Y; Silvennoinen O; Hubbard SR; Zhang T; Gray NS; Li LS
Cell Chem Biol; 2023 Jun; 30(6):618-631.e12. PubMed ID: 37290440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]